The action, started in 2021 by Harbour Antibodies, claimed that Amgen and Teneobio (an Amgen unit) had breached patents guarding Harbour's advanced antibody discovery platform
Delaware jury determines infringement was willful and the patent remains valid, granting the full 20.2 million dollars in compensation; the willful finding also allows the Company to ask the court to triple the sum, raising it potentially to 60.6 million dollars
Harbour BioMed plans to pursue its wider patent holdings, centering on a separate patent carrying much larger monetary stakes that could reach ten times the current award
The outcome marks a total success for Harbour BioMed, confirming the power of its transgenic rodent technology and dedication to safeguarding scientific progress

PRNewswire - Harbour BioMed (the Company; HKEX: 02142), a worldwide biopharmaceutical firm dedicated to creating new antibody treatments for immunology, oncology and further fields, announced today that a jury in the United States District Court for the District of Delaware delivered a clear verdict supporting the Company in its patent infringement suit against Amgen Inc. and Teneobio, Inc. (an Amgen subsidiary) (together, Amgen). The result stands as a full success for Harbour BioMed, confirming the robustness of its proprietary transgenic rodent technology and its resolve to defend scientific advances.

The lawsuit, begun in 2021 by Harbour Antibodies (part of the Harbour BioMed group), charged that Amgen had breached patents protecting the Company's antibody discovery platform, an important invention developed by Professor Frank Grosveld, a founder of Harbour Antibodies (each, Grosveld Patent). As one of the key intellectual property conflicts in the global antibody technology sector, this matter has attracted considerable industry focus since filing. Following years of legal proceedings, the case reached jury trial on June 8, 2026.

Before trial and in response to a Court decision, the Company quickly adjusted its approach by using a targeted two-part plan: vigorously advancing one patent at trial while readying an appeal of the Court's decision on another to the U.S. Court of Appeals for the Federal Circuit. This plan helped the Company keep progress toward securing patent protection for its technology while keeping options open to enforce wider claims.

At trial, Harbour presented strong evidence. After reviewing the facts and final arguments, the jury took only three hours to deliver a unanimous decision favoring the Company on every point: Amgen infringed the Grosveld Patent; the infringement was willful; the Grosveld Patent is valid; and Harbour receives 20,203,704 dollars in damages, the complete sum sought.

The willful infringement finding also permits the Company to request that the judge triple the award, potentially raising it to 60.6 million dollars. This result stands out in the District of Delaware, where sizable jury awards in complex patent matters remain uncommon.

This represents a landmark success for Harbour BioMed, reinforcing the firm as the genuine pioneer of this key technology, said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. The jury's willful infringement determination delivers a strong signal that scientific advances deserve respect, no matter the scale of the organization involved. It highlights our persistence, careful planning, and steady focus on ensuring major scientific contributions receive recognition, respect, and proper payment. This model outcome in the patent conflict will also open a fresh phase for the global antibody patent environment.

Going forward, Harbour BioMed will keep enforcing its broader patent holdings, centering on another patent with notably larger financial stakes that could reach up to ten times the damages granted here. The company stays dedicated to defending its intellectual property across several fronts.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice, HBICE, HCAb PLUS, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies.

SOURCE Harbour BioMed